Device Trial Radar · NCT06948760
Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Jul 23, 2025
Primary completion
Feb 27, 2026
Study completion Mar 10, 2026
Sponsor
- Lead sponsor
- Mark D. DeBoer, MD, MSc., MCRAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Virginia
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years, up to 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)
Conditions
- Type 1 Diabetes
Interventions
Control-IQ insulin pump with Lyumjev insulinDevice
Control-IQ insulin pump with insulin using settings determined by experimental conversion factor
Control-IQ insulin pump with Humalog or NovologDevice
Control-IQ insulin pump with Humalog or Novolog using optimized insulin settings
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time in Range (70-180 mg/dL)Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Virginia Center for Diabetes Technology
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.